112 results about "Mucosal Immune Responses" patented technology

Compositions comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with one or more of CTACK protein, TECK protein, MEC protein and functional fragments thereof and/or an isolated nucleic acid molecule that encodes an protein selected from the group consisting of: CTACK, TECK, MEC and functional fragments thereof are disclosed. Methods of inducing an immune response, including methods of inducing mucosal immune responses, in an individual against an immunogen, using such compositions are disclosed.

Disclosed are vaccines and immunogenic compositions which use live attenuated pathogenic bacteria, such as Salmonella, to deliver ectopic antigens to the mucosal immune system of vertebrates. The attenuated pathogenic bacteria are engineered to secrete the antigen into the periplasmic space of the bacteria or into the environment surrounding the bacteria. The vertebrate mounts a Th2-mediated immune response toward the secreted antigen.

The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. The invention also provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The use of chitosan and/or detoxified ADP-ribosylating toxin adjuvants enhances anti-meningococcal mucosal immune responses and can shift the Th1/Th2 bias of the responses.

An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof.

The invention discloses a streptococcus suis type 2 10 gene-deleted strain and application. The strain is obtained by knocking out 10 genes on the basis of a streptococcus suis type 2 virulent strain, and the preservation serial number is CCTCC NO: M 2015800. The virulence of the strain is significantly reduced compared with that of the parent strain, safety is high, immunogenicity is high, and immunized mice can be protected against the attack of the streptococcus suis type 2 virulent strain after being immunized in an injection or nasal drip or oral administration mode, which shows that the vaccine can effectively activate the mucosal immune system and systemic immunology of a host; meanwhile, a cross protection function on streptococcus suis type 2 virulent strains of different ST types can also be achieved. The vaccine is simple in preparation method and suitable for industrial production; meanwhile, the immunogenicity of the mutant strain is similar to that of a wild virulent strain, and thus the mutant strain can be applied to the development of rapid reagent kits as a standard substance or a whole-cell antigen.

The invention relates to a campylobacter jejuni chitosan nanometer DNA vaccine, a preparation method and application thereof. The campylobacter jejuni chitosan nanometer DNA vaccine is a nano-microcapsule composed of a chitosan and a recombinant plasmid; the recombinant plasmid is a pCAGGS-flaA which consists of a campylobacter jejuni flagellin gene flaA and a eukaryotic expression vector; the flagellin gene flaA has a nucleotide sequence showed by an SEQ NO.1. The campylobacter jejuni chitosan nanometer DNA vaccine is made by dissolving the constructed recombinant plasmid in chitosan solution; the vaccine can also be used for preparing the drugs for preventing chicken campylobacter jejuni. Tests prove that the vaccine can stimulate to produce specific humoral and local mucosal immune response; after oral challenge, the cloaca bacteria exhausting rate shows a significant declining trend, and the number of the campylobacter jejuni in blood, small intestine, large intestine and caecum can be decreased.

The invention discloses a health food suiting child dinners and having the immunity enhancing function. The health food is prepared from the following components in parts by weight: 15-100 parts of yam, 15-100 parts of tuckahoe, 12-90 parts of hawthorn, 12-90 parts of malt, 12-90 parts of mushroom, 10-80 parts of white fungus and 2-40 parts of oligo fructose. The invention is characterized in that traditional Chinese medical herbs in homology of medicine and food are carefully chosen to prepare the prescription capable of replenishing qi to invigorate the spleen and regulate the stomach to enhance the immunity, and the prebiotics (the oligo fructose) is added to the prescription to proliferate beneficial bacteria, optimize the child gastrointestinal microbial community structure and promote the development of the child intestinal mucosal immune system so as to synchronously enhance the child immunity in dual paths.

The invention discloses a vaccine for blocking transmission of echinococcosis pathogeny echinococcus granulosus from a source. The vaccine provided by the invention is a CTB-EgM123 vaccine or a complete set of vaccine consisting of the CTB-EgM123 vaccine and a subunit vaccine of an EgM123 protein recombinant mycobacterium smegmatis vaccine. An active ingredient of the CTB-EgM123 vaccine is a fusion protein formed by fusion of a cholera toxin B subunit and an echinococcus granulosus EgM123 protein; the active ingredient of the EgM123 protein recombinant mycobacterium smegmatis vaccine can express the recombinant mycobacterium smegmatis of the echinococcus granulosus EgM123 protein. The vaccine provided by the invention can stimulate the immune response in a host, improves the immune level of the host, enhances the intestinal mucosal immune response, and plays an important protective role in resisting infection of echinococcosis.

A novel Akkermansia species has been isolated from fresh faeces obtained from the reticulated python. The species has been named Akkermansia glycaniphilus. It is capable of growing on mucus as a sole carbon and nitrogen source. The species can be used as a medicament, probiotic or cosmetic, e.g., for promoting weight loss, for promoting gut mucosal immune system function, for maintaining, restoring and/or increasing the physical integrity of the gut mucosal barrier, and for prevention or treatment of a variety of associated diseases or disorders.

The subject invention provides, for example, a novel approach to specifically induce intranasal and/or oral mucosal as well as humoral antibody response by administrating a mucosal delivery pentabody complex (MDPC). The MDPC is a complex formed by mixing a target antigen and a mucosal delivery pentabody (MDP) that has a strong affinity to the target antigen. The MDP is a fusion protein of a single domain antibody (sdAb; which binds to the target antigen specifically) to a pentamerization domain (which can include the B-subunit of an AB5 toxin family, including the B subunit of cholera toxin (CT) or heat-labile toxin (LT)). The pentamerization domain can self-assemble into a pentamer, through which a pentameric single domain antibody, or a pentabody, is formed.

The invention relates to a mucosal immunoadjuvant inducing Th1 immune response. A bioinformatics technology is applied in the invention, the spatial conformation of a ricin B-chain monoclonal anti-3E1 and Ricin-B compound which has obtained a Chinese invention patent is determined through the action of an antibody-antigen compound, and a molecular stimulation technology is utilized to reasonably determine four Ricin B identifying active regions of 3E1 and derive four nucleotide sequences. Four GFP-nRTB fusion proteins are obtained through a molecular cloning technology. Results of experiments that the four proteins are used to immunize BALB/C mice through a sublingual way three times show that a P1-GFP protein in the four proteins excites Th1 immune response, and a high-level IgG2a antibody is generated. The capability and the possible molecular mechanism of the targeting GFP mucosal immune response of the P1-GFP protein are discussed. The mucosal immunoadjuvant inducing Th1 immune response, which is screened through the above scheme, can be used for preparing vaccines, immunomodifiers or treatment medicines.

The invention relates to a preparation method of a classical swine fever spleen-lymph-sourced compound living vaccine and belongs to the technical field of veterinary biological products. The preparation method of the classical swine fever spleen-lymph-sourced compound living vaccine comprises the following process steps: selecting a domestic rabbit to be inoculated; inoculating; measuring the temperature and observing; harvesting; preparing virus suspension and inspecting; carrying out mixed adsorption on the harvested full-suspension virus bulk and chicken anti-hog cholera virus egg yolk antibody; and adding freezing and drying protecting agent containing an immunopotentiator into antigen antibody compound obtained through adsorption, carrying out split charging, freezing, and carrying out vacuum drying, so that the classical swine fever spleen-lymph-sourced compound living vaccine is obtained. By adopting the preparation method of the classical swine fever spleen-lymph-sourced compound living vaccine, an antibody acquiring route is simple, animal welfare can be improved, manpower and material resources are saved, production cost is greatly reduced, humoral immunity of the living vaccine can be greatly improved, and high neutralizing antibodies can be produced; and the classical swine fever spleen-lymph-sourced compound living vaccine can be applied to piglet immunization, maternal antibody interference can be avoided, no interference is produced to other vaccines, especially a mycoplasma hyopneumoniae vaccine and the like, after the classical swine fever spleen-lymph-sourced compound living vaccine is applied to piglets, and strong mucosal immune response can be induced, so that protection rate is improved.

The present invention provides a method for inducing an immune response to an adenovirus in a subject which has been pre-exposed to an adenovirus or adenoviral vector. The invention further provides a method for inducing a mucosal immune response to an antigen. The methods of the invention are carried out by oral administration of adenoviral vectors.

The invention provides a preparation method of a replication-defective A and D divalent influenza virus attenuated live vaccine. The invention constructs a recombinant virus strain; on the premise ofnot changing gene stability, the constructed recombinant virus can stably and simultaneously express surface protein hemagglutinin HA of A type influenza virus H1N1 subtype and unique surface proteinhemagglutinin esterase fusion protein HEF of D type influenza virus. The constructed attenuated strain has good gene stability and cannot be replicated in an experimental animal body, so the constructed attenuated strain has no pathogenicity; meanwhile, the constructed attenuated strain also can induce a body to produce strong mucosal immune response and cellular immune response level and keeps intense and durable immunogenicity. The key is that a vaccine candidate strain can produce an immunoprotection action on the A type influenza virus H1N1 subtype and the D type influenza virus. Therefore, the replication-defective A and D divalent influenza virus attenuated live vaccine has huge social significance in preventing and controlling A type and D type influenza.

The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response. The present invention provides a mucosal vaccine composition to be administered to at least one mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane, containing: at least one antigen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Serratia, Leclercia, Rahnella, Acidicaldus, Acidiphilium, Acidisphaera, Acidocella, Acidomonas, Asaia, Belnapia, Craurococcus, Gluconacetobacter, Gluconobacter, Kozakia, Leahibacter, Muricoccus, Neoasaia, Oleomonas, Paracraurococcus, Rhodopila, Roseococcus, Rubritepida, Saccharibacter, Stella, Swaminathania, Teichococcus, Zavarzinia, Pseudomonas, Achromobacter, Bacillus, Methanoculleus, Methanosarcina, Clostridium, Micrococcus, Flavobacterium, Pantoea, Acetobacter, Zymomonas, Xanthomonas, and Enterobacter, or a salt thereof.